Across TCGA pan-cancer cohorts, PLEKHN1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PLEKHN1 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PLEKHN1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PLEKHN1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where PLEKHN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	1.000	0.298	.016	16	view →
LSCC	OS	Median	All	0.860	0.513	.024	5	view →
PDAC	DFS	Median	All	0.615	0.876	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PLEKHN1 tumor-vs-normal RNA expression · all PLEKHN1 data types